sever
acut
respiratori
syndrom
sar
lifethreaten
respiratori
diseas
first
report
southern
china
novemb
spread
wide
asian
countri
north
america
europ
accord
world
health
organ
total
peopl
worldwid
becam
sick
sar
outbreak
infect
patient
die
novel
coronaviru
associ
case
sar
sarscov
identifi
etiolog
agent
endem
atyp
pneumonia
sarscov
singlestrand
positivestrand
rna
viru
genom
structur
compris
replicas
structur
region
polyprotein
kda
kda
encod
viral
replicas
gene
subject
extens
proteolyt
process
viral
proteas
produc
multipl
function
subunit
respons
format
replicas
complex
sarscov
proteas
name
proteas
picornavirida
kda
cystein
proteas
cleav
replicas
polyprotein
conserv
site
canon
leuglnfl
ser
ala
gli
sequenc
function
import
sarscov
proteas
viral
life
cycl
togeth
success
develop
efficaci
antivir
agent
target
proteas
virus
enzym
recogn
prime
target
therapeut
intervent
sarscov
infect
xray
crystal
structur
proteas
form
dimer
two
protom
compos
three
domain
activ
site
contain
catalyt
dyad
substratebind
subsit
enzym
absolut
specif
substrat
date
larg
number
inhibitor
proteas
studi
includ
molecul
identifi
highthroughput
screen
electrophil
analogu
isatin
deriv
peptidomimet
bunsatur
ester
peptid
anilid
benzotriazol
ester
howev
molecul
lack
structur
studi
provid
indepth
understand
molecular
interact
enzymeinhibitor
complex
andor
structurebas
optim
four
report
describ
proteas
structur
complex
inhibitor
complex
structur
ligand
irrevers
inhibitor
coval
bound
target
protein
although
sg
atom
enzym
activ
site
display
bond
format
various
methylen
group
chloromethyl
keton
cmk
c
b
atom
michael
acceptor
atom
azapeptid
epoxid
ape
mechanismbas
inhibitor
demonstr
satisfactori
potenc
ic
mm
cmk
ic
mm
k
mm
michael
acceptor
k
mm
ape
proteas
gener
revers
inhibitor
produc
fewer
side
effect
suicid
inhibitor
thu
suitabl
therapeut
develop
noncoval
hiv
proteas
inhibitor
k
nm
previous
develop
laboratori
found
inhibitor
proteas
k
valu
mm
previou
studi
shown
c
h
u
n
g
r
e
n
n
u
n
g
effect
fiv
proteas
mani
drugresist
hiv
proteas
strong
abil
control
lentivir
infect
tissu
cultur
exert
advers
effect
icr
mice
dose
level
mg
kg
gavag
day
studi
period
compound
also
neg
mous
peripher
blood
micronucleu
assay
consider
taken
account
select
lead
compound
optim
search
higher
inhibit
potenc
initi
incorpor
seri
lamino
acid
place
valala
residu
howev
none
enhanc
inhibitori
activ
see
support
inform
neg
result
led
us
suspect
main
bind
mode
energet
domin
two
phenyl
group
optim
inhibitor
proteas
replac
peripher
valala
residu
two
central
phenyl
group
base
rational
bind
mode
proteinligand
complex
mainli
involv
least
dipeptid
scaffold
thu
carri
comput
model
method
explor
dipeptid
model
ligand
possibl
proteinligand
interact
exhaust
explor
dipeptid
bind
mode
use
autom
comput
model
procedur
reveal
trptrp
dipeptid
emerg
strongest
binder
basi
rank
system
use
moreov
toprank
proteinligand
complex
contain
least
one
trp
residu
detail
see
support
inform
thu
synthes
two
compound
test
bind
mode
hypothesi
one
two
trp
group
adjac
central
diol
scheme
two
addit
valala
residu
synthesi
start
ltrp
shown
scheme
cbzltryptophan
convert
weinreb
amid
follow
reduct
give
protect
ltryptophan
aldehyd
subject
stereoselect
pinacol
homocoupl
accord
report
method
yield
diol
success
protect
diol
isopropyliden
indol
nitrogen
tertbutoxycarbonyl
boc
provid
overal
yield
remov
termin
cbz
group
hydrogenolysi
subsequ
coupl
cbzvaloh
produc
adduct
yield
compound
contain
addit
ala
residu
prepar
similar
process
yield
final
deprotect
acid
condit
afford
desir
diol
yield
compound
test
proteas
prove
effect
competit
inhibitor
proteas
k
valu
mm
respect
note
compound
highli
select
proteas
inhibit
observ
hiv
proteas
mm
order
understand
molecular
interact
enzymeinhibitor
complex
detail
carri
xray
crystallographi
analysi
sarscov
proteas
complex
contain
compound
preliminari
result
reveal
conform
chang
presum
induc
presenc
ligand
observ
loop
region
near
activ
site
figur
differenti
electron
densiti
map
presenc
compound
indic
ligand
partial
visibl
molecular
structur
ligand
could
precis
defin
howev
comput
structur
compound
proteas
construct
use
preliminari
xray
protein
structur
obtain
presenc
compound
structur
differ
proteas
structur
use
previou
model
task
previou
structur
deriv
chloromethyl
keton
complex
proteas
expect
round
comput
model
would
produc
realist
proteinligand
complex
model
predict
model
ligand
structur
would
superimpos
onto
differenti
electron
densiti
map
confirm
valid
bind
mode
ligand
target
protein
de
wwwchembiochemorg
scribe
support
inform
predict
model
bind
structur
compound
use
inform
differenti
electron
densiti
map
purpos
use
differenti
electron
densiti
map
independ
test
assess
valid
predict
bind
mode
visual
examin
toprank
proteinligand
complex
structur
gener
three
dock
softwar
packag
reveal
consensu
complex
structur
suggest
tight
pack
two
tryptophan
sidechain
bind
pocket
two
cbz
moieti
occupi
neighbor
site
consensu
particularli
strong
regard
tryptophan
sidechain
conform
precis
hydrogenbind
configur
satisfi
hydrogenbond
donor
tryptophan
side
chain
conserv
throughout
toprank
structur
hydrophob
pack
tryptophan
side
chain
ligandbind
site
tightli
match
induc
hydrogenbond
local
conform
involv
side
chain
fit
perfectli
accommod
tryptophan
sidechain
part
bind
site
model
structur
form
anoth
hydrogenbond
pattern
anoth
indol
group
site
figur
b
bind
conform
cbz
moieti
howev
less
certain
consensu
complex
structur
uncertainti
model
cbz
moieti
ligandprotein
complex
result
lack
favor
interact
cbz
moieti
substrat
bind
site
protein
uncertainti
also
manifest
incomplet
xray
crystallograph
data
cbz
group
pauciti
favor
cbzprotein
interact
complex
model
suggest
possibl
improv
bind
affin
specif
replac
cbz
moieti
function
group
consensu
complex
structur
compar
differenti
densiti
map
show
superimposit
differenti
electron
densiti
map
model
bind
mode
compound
comparison
indic
visibl
fragment
differenti
electron
densiti
map
account
model
ligand
conform
activ
site
especi
posit
indol
group
consist
consensu
model
structur
differenti
electron
densiti
map
support
valid
model
complex
structur
ligandprotein
complex
shown
figur
b
differ
toprank
trptrp
bind
mode
predict
preliminari
model
task
differ
see
figur
retrospect
although
discrep
could
aris
differ
target
protein
structur
ligand
molecul
structur
use
model
task
partial
agreement
two
model
figur
nevertheless
suggest
preliminari
model
effort
provid
product
direct
improv
ligandprotein
bind
affin
subsequ
refin
complex
structur
significantli
improv
accuraci
bind
model
provid
work
model
optim
lead
compound
summari
use
comput
technolog
optim
lead
inhibitor
proteas
c
symmetr
diol
design
synthes
show
higher
affin
previou
lead
compound
one
order
magnitud
inhibit
constant
mm
compound
repres
potent
noncoval
proteas
inhibitor
structur
analys
report
date
success
exampl
lead
optim
comput
model
predict
potenc
select
hiv
proteas
achiev
though
electrondens
map
complex
well
defin
preliminari
xray
structur
use
support
comput
model
analysi
diol
complex
proteas
indic
nh
indol
ring
form
hydrogen
bond
side
chain
believ
approach
provid
platform
lead
optim
